Clinical Trials Logo

Acral Lentiginous Melanoma clinical trials

View clinical trials related to Acral Lentiginous Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04511013 Recruiting - Metastatic Melanoma Clinical Trials

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Start date: September 23, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma.

NCT ID: NCT04244552 Recruiting - Breast Cancer Clinical Trials

First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Start date: February 11, 2020
Phase: Phase 1
Study type: Interventional

ATRC-101-A01 is a first-in-human, Phase 1b, open-label trial to characterize the safety, tolerability, pharmacokinetics (PK), and biological activity of escalating doses of ATRC-101, an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody.

NCT ID: NCT03698019 Recruiting - Mucosal Melanoma Clinical Trials

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Start date: December 6, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.

NCT ID: NCT03025256 Recruiting - Metastatic Melanoma Clinical Trials

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Start date: May 2, 2018
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02978443 Active, not recruiting - Mucosal Melanoma Clinical Trials

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Start date: July 26, 2017
Phase: Phase 2
Study type: Interventional

Participants with advanced or metastatic mucosal melanoma (cohort A) and acral lentiginous melanoma (cohort B) eligible for treatment with nivolumab in combination with ipilimumab followed by nivolumab therapy will submit tissue blocks from tumors of malignant melanoma for histopathology review and immunohistochemistry analysis at Georgetown University-Lombardi Comprehensive Cancer Center. Pretreatment blood will be drawn and stored in the Melanoma Research Foundation Breakthrough Consortium Virtual Repository at each participating institution. At the end of participation, samples will be sent to Georgetown University-Lombardi Comprehensive Cancer Center for processing and storage. An optional pretreatment biopsy of an accessible tumor lesion will be performed in a subset of enrolled patients. Patients will receive nivolumab in combination with ipilimumab according to the standard FDA approved treatment regimen.

NCT ID: NCT02875132 Recruiting - Clinical trials for Acral Lentiginous Melanoma

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab

NCT ID: NCT00937937 Active, not recruiting - Recurrent Melanoma Clinical Trials

Dinaciclib in Treating Patients With Stage IV Melanoma

Start date: July 1, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00424515 Active, not recruiting - Mucosal Melanoma Clinical Trials

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

BUS255
Start date: July 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how effective Imatinib (Gleevec) is in treating acral lentiginous and mucosal melanoma which has spread to other parts of the body in patients who's disease carries a c-kit mutation. Gleevec is a protein-kinase inhibitor. It is believed that Gleevec may be effective in blocking signals on certain cancer cells which allow the malignant cells to multiply and spread.